EGFR-directed therapy in lung cancer:
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generatio...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Cambridge, United Kingdom ; New York, NY, USA
Cambridge University Press
2023
|
| Schriftenreihe: | Cambridge elements: elements in molecular oncology
|
| Schlagworte: | |
| Zusammenfassung: | Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA) |
| Beschreibung: | 35 Seiten Illustrationen, Diagramme 152 x 228 mm |
| ISBN: | 9781009342308 1009342304 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV049346269 | ||
| 003 | DE-604 | ||
| 005 | 20240131 | ||
| 007 | t | ||
| 008 | 230929s2023 a||| |||| 00||| eng d | ||
| 020 | |a 9781009342308 |c Broschur : EUR 20.95 |9 978-1-009-34230-8 | ||
| 020 | |a 1009342304 |9 1-009-34230-4 | ||
| 024 | 3 | |a 9781009342308 | |
| 035 | |a (OCoLC)1422386520 | ||
| 035 | |a (DE-599)BVBBV049346269 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XH 5765 |0 (DE-625)152918:13144 |2 rvk | ||
| 100 | 1 | |a Kim, So Yeon |d ca. 20./21. Jh. |e Verfasser |0 (DE-588)1281749796 |4 aut | |
| 245 | 1 | 0 | |a EGFR-directed therapy in lung cancer |c So Yeon Kim (Yale School of Medicine), Daniel B. Costa (Harvard Medical School), Daisuke Shibahara (Harvard Medical School), Susumu Kobayashi (Harvard Medical School), Balazs Halmos (Albert Einstein College of Medicine) |
| 264 | 1 | |a Cambridge, United Kingdom ; New York, NY, USA |b Cambridge University Press |c 2023 | |
| 300 | |a 35 Seiten |b Illustrationen, Diagramme |c 152 x 228 mm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Cambridge elements: elements in molecular oncology | |
| 520 | |a Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA) | ||
| 650 | 4 | |a Medical diagnosis / BIC2 | |
| 650 | 4 | |a Oncology / BIC2 | |
| 650 | 4 | |a Respiratory medicine / BIC2 | |
| 700 | 1 | |a Costa, Daniel B. |d ca. 20./21. Jh. |e Verfasser |0 (DE-588)1281750212 |4 aut | |
| 700 | 1 | |a Shibahara, Daisuke |d ca. 20./21. Jh. |e Verfasser |0 (DE-588)1281751170 |4 aut | |
| 700 | 1 | |a Kobayashi, Susumu |d ca. 20./21. Jh. |e Verfasser |0 (DE-588)1281751944 |4 aut | |
| 700 | 1 | |a Halmos, Balazs |d ca. 20./21. Jh. |e Verfasser |0 (DE-588)1281752630 |4 aut | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034606738 | ||
Datensatz im Suchindex
| _version_ | 1804185875752419328 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Kim, So Yeon ca. 20./21. Jh Costa, Daniel B. ca. 20./21. Jh Shibahara, Daisuke ca. 20./21. Jh Kobayashi, Susumu ca. 20./21. Jh Halmos, Balazs ca. 20./21. Jh |
| author_GND | (DE-588)1281749796 (DE-588)1281750212 (DE-588)1281751170 (DE-588)1281751944 (DE-588)1281752630 |
| author_facet | Kim, So Yeon ca. 20./21. Jh Costa, Daniel B. ca. 20./21. Jh Shibahara, Daisuke ca. 20./21. Jh Kobayashi, Susumu ca. 20./21. Jh Halmos, Balazs ca. 20./21. Jh |
| author_role | aut aut aut aut aut |
| author_sort | Kim, So Yeon ca. 20./21. Jh |
| author_variant | s y k sy syk d b c db dbc d s ds s k sk b h bh |
| building | Verbundindex |
| bvnumber | BV049346269 |
| classification_rvk | XH 5765 |
| ctrlnum | (OCoLC)1422386520 (DE-599)BVBBV049346269 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02817nam a2200397 c 4500</leader><controlfield tag="001">BV049346269</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240131 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">230929s2023 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781009342308</subfield><subfield code="c">Broschur : EUR 20.95</subfield><subfield code="9">978-1-009-34230-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1009342304</subfield><subfield code="9">1-009-34230-4</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9781009342308</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1422386520</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049346269</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 5765</subfield><subfield code="0">(DE-625)152918:13144</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kim, So Yeon</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1281749796</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">EGFR-directed therapy in lung cancer</subfield><subfield code="c">So Yeon Kim (Yale School of Medicine), Daniel B. Costa (Harvard Medical School), Daisuke Shibahara (Harvard Medical School), Susumu Kobayashi (Harvard Medical School), Balazs Halmos (Albert Einstein College of Medicine)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, United Kingdom ; New York, NY, USA</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">35 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">152 x 228 mm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cambridge elements: elements in molecular oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical diagnosis / BIC2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology / BIC2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory medicine / BIC2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Costa, Daniel B.</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1281750212</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shibahara, Daisuke</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1281751170</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kobayashi, Susumu</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1281751944</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Halmos, Balazs</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1281752630</subfield><subfield code="4">aut</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034606738</subfield></datafield></record></collection> |
| id | DE-604.BV049346269 |
| illustrated | Illustrated |
| index_date | 2024-07-03T22:48:25Z |
| indexdate | 2024-07-10T10:02:11Z |
| institution | BVB |
| isbn | 9781009342308 1009342304 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034606738 |
| oclc_num | 1422386520 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 35 Seiten Illustrationen, Diagramme 152 x 228 mm |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | Cambridge University Press |
| record_format | marc |
| series2 | Cambridge elements: elements in molecular oncology |
| spelling | Kim, So Yeon ca. 20./21. Jh. Verfasser (DE-588)1281749796 aut EGFR-directed therapy in lung cancer So Yeon Kim (Yale School of Medicine), Daniel B. Costa (Harvard Medical School), Daisuke Shibahara (Harvard Medical School), Susumu Kobayashi (Harvard Medical School), Balazs Halmos (Albert Einstein College of Medicine) Cambridge, United Kingdom ; New York, NY, USA Cambridge University Press 2023 35 Seiten Illustrationen, Diagramme 152 x 228 mm txt rdacontent n rdamedia nc rdacarrier Cambridge elements: elements in molecular oncology Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA) Medical diagnosis / BIC2 Oncology / BIC2 Respiratory medicine / BIC2 Costa, Daniel B. ca. 20./21. Jh. Verfasser (DE-588)1281750212 aut Shibahara, Daisuke ca. 20./21. Jh. Verfasser (DE-588)1281751170 aut Kobayashi, Susumu ca. 20./21. Jh. Verfasser (DE-588)1281751944 aut Halmos, Balazs ca. 20./21. Jh. Verfasser (DE-588)1281752630 aut |
| spellingShingle | Kim, So Yeon ca. 20./21. Jh Costa, Daniel B. ca. 20./21. Jh Shibahara, Daisuke ca. 20./21. Jh Kobayashi, Susumu ca. 20./21. Jh Halmos, Balazs ca. 20./21. Jh EGFR-directed therapy in lung cancer Medical diagnosis / BIC2 Oncology / BIC2 Respiratory medicine / BIC2 |
| title | EGFR-directed therapy in lung cancer |
| title_auth | EGFR-directed therapy in lung cancer |
| title_exact_search | EGFR-directed therapy in lung cancer |
| title_exact_search_txtP | EGFR-directed therapy in lung cancer |
| title_full | EGFR-directed therapy in lung cancer So Yeon Kim (Yale School of Medicine), Daniel B. Costa (Harvard Medical School), Daisuke Shibahara (Harvard Medical School), Susumu Kobayashi (Harvard Medical School), Balazs Halmos (Albert Einstein College of Medicine) |
| title_fullStr | EGFR-directed therapy in lung cancer So Yeon Kim (Yale School of Medicine), Daniel B. Costa (Harvard Medical School), Daisuke Shibahara (Harvard Medical School), Susumu Kobayashi (Harvard Medical School), Balazs Halmos (Albert Einstein College of Medicine) |
| title_full_unstemmed | EGFR-directed therapy in lung cancer So Yeon Kim (Yale School of Medicine), Daniel B. Costa (Harvard Medical School), Daisuke Shibahara (Harvard Medical School), Susumu Kobayashi (Harvard Medical School), Balazs Halmos (Albert Einstein College of Medicine) |
| title_short | EGFR-directed therapy in lung cancer |
| title_sort | egfr directed therapy in lung cancer |
| topic | Medical diagnosis / BIC2 Oncology / BIC2 Respiratory medicine / BIC2 |
| topic_facet | Medical diagnosis / BIC2 Oncology / BIC2 Respiratory medicine / BIC2 |
| work_keys_str_mv | AT kimsoyeon egfrdirectedtherapyinlungcancer AT costadanielb egfrdirectedtherapyinlungcancer AT shibaharadaisuke egfrdirectedtherapyinlungcancer AT kobayashisusumu egfrdirectedtherapyinlungcancer AT halmosbalazs egfrdirectedtherapyinlungcancer |